North America Vision Care Market is expected to be valued at US$ 100.72 Billion by 2026

The North America vision care market is projected to register a CAGR of 9.8% during the forecast period and is expected to be valued at US$ 100.72 Bn by the end of 2026. In this report, Future Market Insights analyses the factors and trends impacting the growth and performance of the North America vision care market.

According to Future Market Insights analysts, factors such as rising prevalence of eye diseases leading to eye surgery procedures, an increasing geriatric population, and the introduction of new and advanced vision care products are major factors expected to fuel the revenue growth of the North America vision care market over the forecast period.

Sample of Research Report @
https://www.futuremarketinsights.com/reports/sample/rep-na-2018

Economic factors such as growing healthcare expenditure, increasing disposable income per capita, rising government support in developed economies, and favourable reimbursement policies are also expected to boost the growth of the North America vision care market over the forecast period.

However, rise in the costs of eye surgery and treatment and a risk of infection and vision loss may hinder the growth of the North America vision care market over the forecast period.

Sales of vision care services has remained quite healthy in the U.S. market in the recent years, making North America the most lucrative market globally. The North America vision care market revenue was accounted to be US$ 37.1 Bn in 2015, with the U.S. accounting for majority of revenue share.

Ask the Analyst @
 https://www.futuremarketinsights.com/ask-question/rep-na-2018

Segmentation highlights

The North America vision care market can be broadly classified into six product segments – Rx lenses, frames, non Rx sunglasses, contact lenses, readers, and contact lens solutions – each with different applications.

  • By product, Rx lenses accounted for higher revenue share in North America as compared to other product segments
  • The Frames product type segment accounted for the second largest revenue share followed by the contact lenses product segment in 2015. The contact lenses segment is expected to register the highest CAGR of 12.4% during the forecast period
  • By distribution channel, the retail segment accounted for a higher revenue share in the North America vision care market as compared to other distribution channels
  • The Retail segment is expected to reach a market valuation of US$ 60.6 Bn by 2026, reflecting a CAGR of 9.8% over the forecast period
  • The E-commerce segment is also expanding at a higher rate in the overall North America vision care market. This segment is expected to reach US$ 18.9 Bn by the end of 2026, registering a CAGR of 3.8% over the forecast period.

Request for Customization @
https://www.futuremarketinsights.com/customization-available/rep-na-2018

Vendor insights

Key players in the North America vision care market include:

  • Johnson & Johnson Vision Care Inc.
  • Valeant Pharmaceuticals International Inc.
  • Novartis AG, The Cooper Companies Inc.
  • SynergEyes Inc.
  • Luxottica
  • Essilor International
  • ZEISS International

Major market players are adopting different strategies such as partnerships and acquisitions to maintain and expand their market share. Recently in January 2016, Valeant Pharmaceuticals expanded its specialty lens business with the addition of Alden Optical Laboratories Inc. In 2016, Essilor International reinforced its expansion with independent eye care professionals in the U.S with the acquisition of Vision Source.

Key Segments

By Product Type:

  • Rx-Lenses
  • Frames
  • Contact Lenses
  • Non Rx Sunglasses
  • Reading Glasses
  • Contact Lens Solutions

By Distribution Channel:

  • Retail Stores
  • E-Commerce
  • Clinics
  • Hospitals

By Country:

  • U.S.
  • Canada

About Future Market Insights (FMI) 

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact:

Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedInTwitterBlogs

Molluscum Contagiosum (MC) Treatment Market by registering a CAGR of 5% from 2023 to 2033

The global Molluscum Contagiosum (MC) Treatment Market is expected to grow significantly from 2018 to 2022, with a continued upward trajectory in demand from 2023 to 2033. Factors such as increasing prevalence of MC, growing awareness and diagnosis rates, availability of advanced treatment options, and high healthcare expenditure are expected to drive market growth during this period. According to a new market research report published by Future Market insights, the global Molluscum Contagiosum (MC) Treatment market is expected to grow at a CAGR of 5% from 2023 to 2033, reaching a market size of USD 4.89 Billion by 2033.

The report highlights that the prevalence of MC is increasing worldwide, with a growing number of cases being reported each year. This is driving the demand for MC treatment, which is expected to continue to rise in the coming years. The report also notes that there is a growing awareness of MC among the general population, leading to more people seeking medical attention for the infection.

Get Latest Sample Copy@ https://www.futuremarketinsights.com/reports/sample/rep-gb-16795

The availability of advanced treatment options is another key factor driving the growth of the MC treatment market. The report highlights that there are a range of treatment options available for MC, including topical creams, cryotherapy, and laser therapy. Key players in the market are investing in research and development to develop new and advanced treatment options, which is driving market growth.

Key Takeaways from the Market Study

  • From 2018 to 2022, the Molluscum Contagiosum (MC) Treatment market grew at a CAGR of 3.5%.
  • The global Molluscum Contagiosum (MC) Treatment market is expected to grow with a 5% CAGR during 2023 to 2033.
  • As of 2033, the Molluscum Contagiosum (MC) Treatment Market is expected to reach US$ 4.89 Billion.
  • According to the FMI analysis, surgical treatment accounts for the largest market share.
  • North America is expected to possess 40% market share for the Molluscum Contagiosum (MC) Treatment market.
  • The East & South Asia market is predicted to increase significantly throughout the forecast period, with a share of 20% during the forecast period.

A series of international level collaborations involving healthcare stakeholders across various institutional settings are fueling further clinical trials and research studies dedicated to discovering Molluscum Contagiosum (MC) Treatment.” says an FMI analyst

Ask An Analyst @ https://www.futuremarketinsights.com/ask-question/rep-gb-16795

Market Competition

Key players in the market include companies such as Competition Deep Dive, Novan, Inc., Veloce Biopharma, Gurina Foundation, Azafaros, Polaryx Therapeutics, Abbott Medtronic, Merck & Co., Inc., Pfizer Inc., Siemens Healthcare GmbH, Novartis AG, along with healthcare providers and technology companies among other global players.

  • In January 2023, Novan, Inc. announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for berdazimer gel, 10.3% (SB206) for the treatment of molluscum contagiosum. The filing is expected to be reviewed within a typical 12-month period, with a potential approval date in the first quarter of 2024 if accepted. Results from the pivotal Phase 3 B-SIMPLE4 clinical study evaluating berdazimer gel, 10.3% were highly statistically significant and demonstrated improvement in primary clinical endpoint, and the product was found to be well tolerated with mild adverse events reported.

More Insights Available

FMI, in its new offering, presents an unbiased analysis of the global Molluscum Contagiosum (MC) Treatment market, presenting historical analysis from 2018 to 2022 and forecast statistics for the period of 2023 to 2033.

The study reveals essential insights on the basis of type, treatment, end-user & Region.

Request Discount@ https://www.futuremarketinsights.com/request-discount/rep-gb-16795

Key Segments Profiled in the Molluscum Contagiosum (MC) Treatment Industry Survey

Therapy:

  • Cryotherapy
  • Curettage
  • Immune-modulating Therapies
  • Topical Therapies

End-User:

  • Hospital
  • Skin Clinics
  • Immunocompromised Patients

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006, Jumeirah Bay 2, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
LinkedInTwitterBlogs
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com

Meningococcal Meningitis Treatment Market is expected to register a CAGR of 4.7% from 2023 to 2033

During the forecast period 2023 to 2033, the Meningococcal meningitis treatment market is expected to grow at a value of 4.7% CAGR, according to Future Market Insights. By the year 2033, the global market for Meningococcal meningitis treatment is expected to rise up to a market valuation of US$ 283 Million. Growth of the market can be attributed to increasing prevalence of the disease, availability of vaccines, and the growing awareness about the disease. In regions where the disease is more common, such as the meningitis belt in sub-Saharan Africa, the market for treatment is particularly significant.

The primary treatment for meningococcal meningitis is antibiotics, such as penicillin, ceftriaxone, or ciprofloxacin, to kill the bacteria causing the infection. Supportive care, including hospitalization, intravenous fluids, and oxygen therapy, is also essential for individuals with meningococcal meningitis.

The meningococcal meningitis treatment market is expected to continue to grow in the coming years, driven by increasing awareness about the disease, improvements in treatment options, and the availability of vaccines. Additionally, the rising incidence of the disease in some regions, such as Europe and North America, is likely to contribute to the growth of the market.

Get Latest Sample Copy@ https://www.futuremarketinsights.com/reports/sample/rep-gb-16794

In conclusion, the meningococcal meningitis treatment market is significant due to the high incidence of the disease worldwide. Treatment typically involves antibiotics and supportive care, while vaccination is an important preventive measure. The market is expected to continue to grow in the coming years, driven by several factors, including the increasing prevalence of the disease and the availability of vaccines.

Key Takeaways from the Market Study

  • Meningococcal meningitis treatment market is expected to grow at a value of 4.7% CAGR in the forecast period 2023 to 2033
  • By treatment type, antibiotic therapy is expected to hold 45% of the market share in 2023 for Meningococcal Meningitis treatment market.
  • North America is expected to possess 47% market share for Meningococcal Meningitis treatment market in 2023.
  • Europe Meningococcal Meningitis treatment market size is expected to possess 42% market share in 2023.

“Development of antibiotic therapies and vaccines along with research and development is expected to drive the growth of the market in the upcoming years.” states an FMI analyst

Ask An Analyst @ https://www.futuremarketinsights.com/ask-question/rep-gb-16794

Competitive Landscape

Key players in the Meningococcal Meningitis treatment market are Biomed Pvt. Ltd, Novartis, Nuron Biotech, Pfizer, Baxter, Merck & Co., Sanofi, GlaxoSmithKline Plc., F. Hoffmann-La Roche Ltd., Athlone Laboratories and Wockhardt Ltd.

  • Novartis has conducted research into new treatments for meningococcal meningitis. For example, the company has worked on the development of a monoclonal antibody therapy for the disease, which aims to neutralize the bacteria responsible for meningococcal meningitis.
  • Nuron Biotech is a biotechnology company that has been involved in the development and production of a meningococcal vaccine called Menomune. Menomune is a vaccine used to help protect against four different strains of meningococcal disease (A, C, Y, and W-135). The vaccine is approved for use in individuals aged 2 years and older in several countries around the world.

More Valuable Insights

Future Market Insights, in its new offering, presents an unbiased analysis of the global Meningococcal meningitis treatment market, presenting historical analysis from 2018 to 2022 and forecast statistics for the period of 2023 to 2033.

The study reveals essential insights on the basis of Causative Micro-organism (Bacterial, Viral, Fungal), Treatment Type (Antibiotic Therapy and Adjunctive Therapy), Route of Administration (Injectable and Oral), Vaccine Type (Meningococcal Conjugate Vaccine, Meningococcal Polysaccharide Vaccine, Combination Vaccine) Distribution channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) Region (North America, Latin America, Europe, South Asia, East Asia, Oceania, Middle East & Africa)

Request Discount@ https://www.futuremarketinsights.com/request-discount/rep-gb-16794

Key Segments Profiled in the Meningococcal Meningitis Treatment Industry Survey

Causative Micro-organism:

  • Bacterial
  • Viral
  • Fungal

Treatment Type:

  • Antibiotic Therapy
    • Penicillin
    • Ampicillin
    • Chloramphenicol
    • Ceftriaxone
    • Adjunctive Therapy

Route of Administration:

  • Injectable
  • Oral

Vaccine Type:

  • Meningococcal Conjugate Vaccine
  • Meningococcal Polysaccharide Vaccine
  • Combination Vaccine

Distribution channel:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006, Jumeirah Bay 2, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
LinkedInTwitterBlogs
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com

Prosthetic Heart Valve Market is projected to grow at a prolific CAGR of 11.4% by 2032

The Prosthetic Heart Valve Market was estimated at US$ 10.9 billion in 2021, and by the end of 2022, it is anticipated to reach US$ 12.3 billion. Because valvular disorders like aortic stenosis (AS), organic and ischemic (functional) mitral regurgitation, and tricuspid regurgitation are becoming more common, it is anticipated that worldwide demand for prosthetic valves will increase significantly between 2022 and 2032, reaching US$ 36.3 billion.

However, high costs associated with transcatheter heart valve products, procedure related risks and complications, and product recalls are some restraints likely to hamper the growth of the global prosthetic heart valve market over the forecast period.

Request a Sample of this Report @
https://www.futuremarketinsights.com/reports/sample/rep-gb-666

Segmental Forecast:

  • The Transcatheter Heart Valves product type segment is estimated to be valued at US$ 6,069.1 Mn by 2026 end, registering a CAGR of 13.3% between 2016 and 2026
  • The Hospitals end user segment accounted for 74.5% market share of the global prosthetic heart valve market in 2015. Rising demand for quicker treatment options and remedies is expected to promote the revenue growth of the Hospitals segment over the forecast period

Regional Market Overview:

The global prosthetic heart valve market is segmented by region into North America, Latin America Excluding Brazil, Brazil, Western Europe, Eastern Europe, Asia Pacific Excluding Japan (APEJ), and Middle East & Africa (MEA). The global prosthetic heart valve market is largely prominent in the developed regions.

The North America regional market is estimated to witness the highest CAGR of 12.4% during the forecast period followed by the Western Europe regional market at 12.1%.

Factors such as legislative openness and inline approval procedures are expected to contribute largely to the revenue generation potential and attractiveness of the Western Europe prosthetic heart valve market. Rising adoption of transcatheter heart valves in geriatric patients for better care is expected to fuel revenue growth in the Japan prosthetic heart valve market over the forecast period.

Request for Customization @
https://www.futuremarketinsights.com/customization-available/rep-gb-666

Leading market players are focusing on delivering differentiated therapies to cardiac patients and are strengthening their foothold in the global prosthetic heart valve market through strategic collaborations and acquisitions.

Key strategies adopted by most of the major players in the global prosthetic heart valve market include: product approvals and commercialization, leveraging existing capabilities to create patient-centric technologies, briskly entering markets in emerging countries and offering the latest innovative technologies to healthcare facilities and, thus strengthening regional proficiency and addressing customer needs. New product launches, innovation and expansion are anticipated to form the core of these strategies during the forecast period.

Prosthetic Heart Valve Market Key Segmentation:

By Product Type

  • Mechanical Heart Valves
  • Mechanical Aortic Valve
  • Mechanical Mitral Valve
  • Biological/Tissue Heart Valves
  • Tissue Aortic Valve
  • Tissue Mitral Valve
  • Transcatheter Heart Valves
  • Transcatheter Aortic Valve
  • Transcatheter Mitral Valve

By End User

  • Hospitals
  • Ambulatory Surgery Centres

By Region

  • North America
  • Latin America Excluding Brazil
  • Brazil
  • Western Europe
  • Eastern Europe
  • Asia Pacific Excluding Japan (APEJ)
  • Middle East & Africa (MEA)

Speak to our Research Expert @
https://www.futuremarketinsights.com/ask-question/rep-gb-666

About Future Market Insights (FMI) 

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact:

Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedInTwitterBlogs

Post-Traumatic Stress Disorder (PTSD) Treatment Market is expected to grow with a 5% CAGR during 2023 to 2033

During the forecast period 2023 to 2033, the post-traumatic stress disorder (PTSD) treatment market is expected to grow at a value of 5% CAGR, according to Future Market Insights. By the year 2033, the global market for post-traumatic stress disorder (PTSD) treatment is expected to rise up to a market valuation of US$ 27.37 billion. Growth of the market can be attributed to increasing prevalence of PTSD worldwide.

Get Latest Sample Copy@ https://www.futuremarketinsights.com/reports/sample/rep-gb-16801

There is also a growing focus on the use of digital therapeutics and other non-pharmacological interventions for the treatment of PTSD. One example is the use of virtual reality exposure therapy (VRET), which has shown promising results in reducing PTSD symptoms by allowing individuals to confront their trauma in a safe and controlled environment. Several companies, including Limbix and Psious, are developing VRET platforms for the treatment of PTSD and other mental health conditions.

Key Takeaways from the Market Study

  • The post-traumatic stress disorder (PTSD) treatment market is expected to grow at a value of 5% CAGR in the forecast period 2023 to 2033.
  • By drug class, antidepressants are expected to hold 41% of the market share in 2023 for post-traumatic stress disorder (PTSD) treatment market.
  • North America is expected to possess 43% market share for post-traumatic stress disorder (PTSD) treatment market in 2023.
  • Europe post-traumatic stress disorder (PTSD) treatment market size is expected to possess 42% market share in 2023.

“As the prevalence of PTSD continues to rise, the need for effective and accessible treatments will only become more pressing. While there is still much work to be done, the growing focus on PTSD treatment is a positive step forward in improving the lives of individuals affected by this debilitating condition,”states an FMI analyst.

Ask An Analyst @ https://www.futuremarketinsights.com/ask-question/rep-gb-16801

Competitive Landscape

Key players in the post-traumatic stress disorder (PTSD) treatment market are Jazz Pharmaceuticals, Aptinyx, Otsuka Pharmaceutical Development & Commercialization, Inc., Bionomics Limited, Merck KGaA, Pfizer Inc., Aurobindo Pharma Limited, GlaxoSmithKline plc, Viatris Inc., Jubilant Pharmova

  • Otsuka has also partnered with the U.S. Department of Veterans Affairs (VA) to conduct a clinical trial of a medication called samidorphan (ALKS 5461) for the treatment of PTSD. Samidorphan is an opioid system modulator that is being investigated for its ability to reduce symptoms of PTSD, including anxiety, depression, and hyperarousal.
  • Bionomics Limited is a biopharmaceutical company that has developed a medication called BNC210, which is being investigated as a potential treatment for PTSD (Post-Traumatic Stress Disorder). BNC210 is a small molecule drug that acts as a negative allosteric modulator of the α7 nicotinic acetylcholine receptor (α7 nAChR), which is thought to play a role in the development and maintenance of PTSD symptoms.

More Valuable Insights

Future Market Insights, in its new offering, presents an unbiased analysis of the global Post-traumatic stress disorder (PTSD) treatment market, presenting historical analysis from 2018 to 2022 and forecast statistics for the period of 2023 to 2033.

The study reveals essential insights on the basis of Drug Class (Antidepressants, Anti-anxiety Drugs, Antipsychotics, Other Drug Classes) Distribution Channel (Retail Pharmacies and Online Pharmacies) Region (North America, Latin America, Europe, South Asia, East Asia, Oceania, Middle East & Africa)

Request Discount@ https://www.futuremarketinsights.com/request-discount/rep-gb-16801

Key Segments Profiled in the Post-Traumatic Stress Disorder (PTSD) Treatment Industry Survey

By Drug Class:

  • Antidepressants
  • Anti-anxiety Drugs
  • Antipsychotics
  • Other Drug Classes

By Distribution Channel:

  • Retail Pharmacies
  • Online Pharmacies

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006, Jumeirah Bay 2, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
LinkedInTwitterBlogs
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com

Coronary Stents Market is expected to grow at a 5.1% CAGR

According to the most recent Future Market Insights (FMI) report, the demand for portable and coronary stents market will increase significantly over the next few years.

The demand for interventional cardiology care is being fuelled by the rising prevalence of coronary artery disease. Angioplasty is the first choice of treatment for patients with long-term CAD.

Over the last few years, companies in the cardiovascular diagnostic segment are making major investments in order to introduce innovative coronary stents to capitalize on lucrative opportunities in the interventional vascular devices market. Also, companies are working on key related issues of drug eluting stents and working on a comprehensive model of drug release from these stents and the subsequent uptake of the drug into arterial tissue.

For instance, in the past recent years, Abbott received FDA approval for its bioresorbable heart stent absorb, making the first-of-its-kind medical device commercially available to treat people with coronary artery disease in the U.S.

Request Sample Report @
https://www.futuremarketinsights.com/reports/sample/rep-gb-1993

Key Takeaways from Coronary Stents Market Study

  • In terms of raw material, the coronary stents market is expected to witness substantial growth in the next few years. Currently, polymer segment accounts for major share of the global Coronary Stents market.
  • North America has been estimated to dominate the coronary stents market with maximum market share in 2019.
  • The primary trend in the coronary stents market is an increasing number of local manufacturers of coronary stents. Also, growth in interventional cardiology procedures, is an ongoing trend in the coronary stents market.

“Increase in number of cardiac catheterization laboratories and increasing prevalence of cardiovascular diseases are the main factors that will continue to drive the growth of the coronary stents.” says the FMI Analyst.

Increasing Manufacturing Practices across Low Cost Geographies, Boosts the Coronary Stents Market

Transfer of medical device manufacturing practices across low cost geographies such as India, China, South Africa, ASEAN and other Asian countries is expected to fuel growth of the global coronary stents market. Companies offering hospital supplies are targeting price-sensitive geographies through mergers and acquisitions. Leading manufacturers of coronary stents are acquiring domestic players to gain maximum market share in local markets. Moreover, these companies are focusing on low cost product launches in these region owing to large patient pool belonging to the lower middle income group.

Speak to our Research Expert @
https://www.futuremarketinsights.com/ask-question/rep-gb-1993

Want more insights?

Coronary Stents Market, a new study from Future Market Insights, provides unparalleled insights on evolution of the Coronary Stents market during 2014 – 2018 and presents demand projections during 2020 – 2026 on the basis of product (drug eluting stents, bare metal stents and bioresorbable vascular stents), raw material (cobalt chromium, stainless steel, platinum-chromium, nickel titanium and polymer), end user (hospitals, public hospitals, private hospitals, ambulatory surgical centers and cardiac catheterization laboratories), across seven prominent regions.

Coronary Stents Market Structure Analysis

Tier I companies in the coronary stents market include

  • Abbot Vascular
  • Medtronic Inc.
  • Terumo Corporation
  • Boston Scientific and few other key players.

Request for Customization @
https://www.futuremarketinsights.com/customization-available/rep-gb-1993

Key Segment

By Raw Material:

  • Cobalt Chromium
  • Stainless Steel
  • Platinum – Chromium
  • Nickel – Titanium
  • Polymer

By End User:

  • Hospitals
  • Ambulatory Surgical Centers
  • Cardiac Catheterization Laboratories

By Region:

  • North America
  • Latin America
  • Brazil
  • Western Europe
  • Eastern Europe
  • Asia Pacific Excluding Japan
  • Japan
  • Middle East and Africa (MEA)

By Product:

  • Drug Eluting Stent (DES)
  • Bare Metal Stent (BMS)
  • Bioresorbable Vascular Stent (BVS)

About Future Market Insights (FMI) 

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact:

Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedInTwitterBlogs

Preclinical Imaging Market is anticipated to valuation of US$ 4.7 Billion by 2032

The market for preclinical imaging is anticipated to reach a value of US$ 3.3 billion in 2022 and then grow at a CAGR of 3.5% to US$ 4.7 billion by the end of 2032. According to a recent analysis by Future Market Insights, MRI imaging will dominate the global preclinical imaging market in 2021 with a share of roughly 18.9%.

Breathalyzer is a non-invasive medical device used for estimation of Blood Alcohol content (BAC) from breath sample. Breathalyzer is used to test intoxication levels caused by alcohol and drugs. Breathalyzer was invented by Dr. Robert Borkenstein while being appointed as police photographer at Indiana State Police lab.

Since 1954, Breathalyzer is a genericized trademark for many instruments like Alcotest, Alcosensor, Datamaster, Intoxilyzer and Intoximeter. Breathalyzer device consists of three parts, first part consists of system where breath is sampled, second part consists of two glass tubes with chemicals and third part consists of photocells that are connected to meter showing colour change.

Sample of Research Report @
https://www.futuremarketinsights.com/reports/sample/rep-gb-2286

Breathalyzer system together works on redox reaction causes change in colour that is directly proportional to amount of alcohol in breath, wherein red-orange colour of dichromate ion changes to green.

Breathalyzer has been of importance in point-of-care services where initially it was necessary to draw blood out of the body and sent to the hospital to test alcohol concentration in blood, thus making the test time consuming. Till date it has been most important device to monitor and regulate drink and drive accidents or cases.

In 2015 in US, there were about 290,000 people injured and about 10,265 died in drunk driving cases. Also there have been published reports on loss of work quality and time due to alcohol consumption. All over the world it is a legal offense to be detected of alcohol during working hours and while driving.

The driver is charged fine or respective legal action is taken against him if his Blood Alcohol Concentration (BAC) is found out to be above normal (0.08). Also strict actions are taken against employees in government or private sectors if they are detected of alcohol consumption during office hours.

Due to use of Breathalyzer there is no need of any invasive procedure, device is portable and test results are out in seconds. Another important use of Breathalyzer is in maintaining high order discipline in National and International air transport to maintain safety and standards while travelling.

Ask the Analyst @
https://www.futuremarketinsights.com/askus/rep-gb-2286 

Breathalyzer is of very significant use to prevent order and discipline in government or private offices, road traffic management and forensic studies too. It is also used for management in rehabilitation centres, mining and construction centres.

Point-of-Care Breathalyzer Market: Drivers and Restraints

Point-of-care Breathalyzer market has seen enormous growth due to its significant use to maintain safety, order and discipline amongst population. The major drivers for point-of-care Breathalyzer market is alarming increase in alcohol consumption seen at all age groups and also increase in road accidents due to drink driving.

Due to strict government regulations, drink driving and alcohol abuse during work hours has led to increase in demand for modern use portable Breathalyzer. Use of personal portable Breathalyzer to check for alcohol content within normal limits to keep a check on safe driving and productive working hours has given a drive for point-of-care Breathalyzer market worldwide.

Moreover, easy availability of personal Breathalyzer that can be ordered online according to one’s choice, has also been a factor to drive point-of-care Breathalyzer market. Awareness initiative taken by government has also led to increase of market size for point-of-care Breathalyzer market.

High cost of Breathalyzer and less market for new brands producing Breathalyzer were seen to hamper in the past for but modern portable cheap Breathalyzer are taking over the point-of-care Breathalyzer market now.

Request for Customization @
https://www.futuremarketinsights.com/customization-available/rep-gb-2286

Point-of-Care Breathalyzer Market: Overview

According to a study report published in South Africa about 10% of the country’s GDP is lost due to alcohol abuse annually which is equal to R240 billion. Also worldwide there is much loss due to alcohol abuse leading to immense destruction in drunk driving accidents, expensive alcohol abuse treatment and loss of manpower and productive working hours brings an overall effect on worldwide economy.

Thus awareness due to such losses have led government to take strict measures in field of law enforcement and highway safety administration to bring down losses. Efficient use of point-of-care Breathalyzer to prevent such loss has proved beneficial and made people aware of its legal consequences being the reason for increasing market for of point-of-care Breathalyzer market.

Mandatory alcohol test are carried out worldwide in workplaces such as transport, construction sites mining, shipping, airlines, defense centres, rehabilitation centres to maintain safety of individuals increasing market size for point-of-care Breathalyzer market over globe.

Point-of-Care Breathalyzer Market: Segmentation

The global point-of-care breathalyzer market is classified on the basis of product type, product technology, end user and geography.

Based on product type, the point-of-care breathalyzer market is segmented into the following:

  • Non-portable.

Based on product technology, the point-of-care breathalyzer market is segmented into the following:

  • Chemical reaction (Breathalyzer).
  • Fuel-cell technology (Alcosensor III or IV).
  • Infrared Spectroscopy (Intoxilyzer).

Based on end user, the point-of-care breathalyzer market is segmented into the following:

  • International and National transport systems.
  • Rehabilitation centres.
  • Government and private offices.
  • Diagnostic centers.
  • Home care settings.

About Future Market Insights (FMI) 

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact:

Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedInTwitterBlogs

Sphingolipids Market is anticipated to value US$ 991.8 Million by the end of 2032

The market for sphingolipids was anticipated to be worth approximately US$ 564.0 million in 2021, and it is predicted to grow at a CAGR of 5.1% to be worth around US$ 991.8 million by the end of 2032. As of 2021, conventional lipid-based drug delivery systems (LBDDS), which hold a 61.9% global market share, are the market’s dominant force.

The global market for sphingolipid products is expanding rapidly as a result of rapid molecular and biological customization in the sphingolipid components/ formulations and the increasing prevalence of cardiovascular diseases worldwide coupled with an elderly population.  During the forecast period, the market is anticipated to be driven by an increase in the use of natural, synthetic, and semi-synthetic sphingolipids and monomers in the creation of various pharmaceutical formulations.

As the sphingolipids market is not reaching its potential as per the asked demand, due to unexplored benefits of sphingolipids in the healthcare sector, and the side effects of the consumption of sphingolipids inappropriately, the companies are introducing novel sphingolipids components/formulations with minimal side effects at reasonable costs.

Request a Sample of this Report @
https://www.futuremarketinsights.com/reports/sample/rep-gb-15713

This factor might significantly improve the adoption and consumption of pharmaceutical sphingolipids. The rising product launches and approvals are expected to contribute to the market growth over the forecast period too.

Key Takeaways from Market Study

  • Sphingomyelin is the leading segment as a product and holds approximately 0% market share in 2021, due to its anti-cancer, bacteriostatic, and cholesterol-lowering characteristics.
  • Synthetic sphingolipids are the leading segment by source, and held about 4% market share in 2021, owing to their potential as therapeutic prospects for treating a range of medical problems.
  • Conventional lipid-based drug delivery systems (LBDDS) is the leading segment in terms of application holding about 9% of the market share, as compared to traditional tablets or powder-filled capsules, as they can improve bioavailability and reduce dissolving rate-limited absorption because of their pharmacological composition in a solubilized condition.
  • Semi-solid form of sphingolipids is the leading form as of 2021, withholding about 3% of the global market share, owing to the property of reduced adverse side effects when a high drug load is applied to the area where the medication is actually required.
  • Pharmaceutical companies are the leading end users of the global market as of 2021, withholding about 5% of the market share, because of increased outsourcing, innovative modalities, and creative patient outreach tactics.
  • By region, North America is leading in the global sphingolipids market and is expected to continue to do so with a projected CAGR of 4% during the forecasted years.

“Rising initiatives to promote health benefits of sphingolipids products, as well as the increasing ongoing research and development in modifying novel sphingolipids formulations is set to propel the market of sphingolipids across the globe,” says an analyst of Future Market Insights.

Request for Customization @
https://www.futuremarketinsights.com/customization-available/rep-gb-15713

Market Competition

Companies are actively working to increase their market share in this industry by forming strategic agreements to diversify their respective service offerings and sphingolipid production capacities.

  • In January 2022, Pfizer and Acuitas Therapeutics reached an agreement on Lipid Nanoparticle Delivery System for mRNA vaccines and therapeutics.
  • June 2022: To support customers’ scientific research, CD Bioparticles, enlarged its lipid system portfolio and introduced a number of Sphingolipids products. With the addition of Phosphosphingolipids, Ceramides, Sphingolipid Metabolism, Sphingosines, Glycosphingolipids, Phytosphingosine, and Sphingomyelin, researchers now have more options to choose from and employ in lipid system applications.

What Does the Report Cover?

Future Market Insights offers a unique perspective and actionable insights on the sphingolipids market in its latest study, presenting a historical demand assessment of 2012 – 2021 and projections for 2022 – 2032.

The research study is based on the product (ceramide, sphingomyelin, glucosylceramide (GlcCer), lactosylceramide (LacCer), ganglioside GM3, and Other), source (synthetic, semi-synthetic, and natural), application (conventional lipid-based drug delivery systems (LBDDS), self-emulsifying drug delivery systems (SEDDS), self-micro emulsifying drug delivery systems (SMEDDS), liposomes, solid lipid nanoparticles, nanostructured lipid carriers, and others), form (liquid, semi-solid, and solid), and end user (pharmaceutical companies, biopharmaceutical companies, academics, and research institutes, and others), across seven key regions of the world.

About Healthcare Division at Future Market Insights

Future Market Insights facilitates corporates, government, investors, and associated audiences in the healthcare sector to identify and accentuate vital aspects applicable to product strategy, regulatory landscape, technology evolution, and other crucial issues to achieve sustainable success. Our unique approach to gathering market intelligence equips you in devising innovation-driven trajectories for your business. Know more about our sector coverage here.

Ask the Analyst @
https://www.futuremarketinsights.com/ask-question/rep-gb-15713

Key Segments Covered In Sphingolipids Industry Research

By Product:

  • Ceramide
  • Sphingomyelin
  • Glucosylceramide (GlcCer)
  • Lactosylceramide (LacCer)
  • Ganglioside GM3
  • Other

By Source:

  • Synthetic
  • Semi-synthetic
  • Natural

By Application:

  • Conventional Lipid-based Drug Delivery Systems (LBDDS)
  • Self-Emulsifying Drug Delivery Systems (SEDDS)
  • Self-Microemulsifying Drug Delivery Systems (SMEDDS)
  • Liposomes
  • Solid Lipid Nanoparticles
  • Nanostructured Lipid Carriers
  • Others

By Form:

  • Liquid
  • Semi-solid
  • Solid

By End User:

  • Pharmaceutical Companies
  • Biopharmaceutical Companies
  • Academics and Research Institutes
  • Others

About Future Market Insights (FMI) 

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact:

Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedInTwitterBlogs

Surface Plasmon Resonance Market is expected to CAGR of 7.1% by 2032

Surface plasmon resonance market growth is anticipated, rising from US$ 910.4 million in 2022 to US$ 1807.7 million in 2032. The market is expected to grow at a CAGR of 7.1% over the course of the forecast period, according to FMI.

Increasing adoption of label-free detection techniques over labelled detection techniques is due to their cost-effective nature. Additionally, the availability of versatile products coupled with surface plasmon resonance to enhance the specificity of tests is an important factor that will bolster the demand for surface plasmon resonance.

Request a Sample of this Report @
https://www.futuremarketinsights.com/reports/sample/rep-gb-962

Imaging systems help in increasing throughput at a remarkable speed and with precise motion and consistency in report generation. Furthermore, the introduction of multifunctional products for improved outcomes is also expected to drive the growth of the surface plasmon resonance market over the forecast period.

 “Increasing application of surface plasmon resonance in the field of drug discovery and medical imaging is contributing to the growth of the surface plasmon resonance market. Development of new technologies coupled with surface plasmon resonance, such as nanoparticle surface plasmon resonance and microfluidics, is playing an important role in the overall growth of the global surface plasmon resonance market.”

Key Takeaways of Surface Plasmon Resonance Market Study

  • The market share of imaging systems is evaluated to grow at a significant rate by the end of 2029, as these are the ideal solution for the analysis of label-free and multiplexed biomolecules.
  • Sales of surface plasmon resonance are envisaged to be higher in North America. Increasing adoption of imaging systems and biosensors in life science R&D is anticipated to boost the growth of the surface plasmon resonance market in the region.
  • Innovation while developing imaging software used in surface plasmon resonance for the analysis of kinetic parameters of biomolecular interactions is a key aspect for increasing the reproducibility of results. Companies are investing in R&D initiatives to introduce superior imaging devices with enhanced magnification, to observe the smallest deflection in the refractive index, thus aiding the growth of the surface plasmon resonance market.

Request for Customization @
https://www.futuremarketinsights.com/customization-available/rep-gb-962

Adoption of Label-free Detection Technique for Analysis of Biomolecules

Detection of biological analytes through their physical properties is difficult. As a result, researchers rely on the addition of some sort of label to one or more of the analytes that need to be studied. Inclusion of this label for increasing specificity and accuracy has increased the cost of reagents and assays. To reduce assay cost and complexity while providing more qualitative information through labelled detection, adoption of the label-free detection technique such as surface plasmon resonance has increased, and is expected to fuel the growth of the global surface plasmon resonance market during the forecast period.

The label-free detection technique simplifies the procedure by reducing the time and effort required for the development of the assay. Thus, increasing adoption of label-free detection techniques over labelled detection is expected to boost the growth of the global surface plasmon resonance market.

Want more insights?

The surface plasmon resonance market report, a new study by Future Market Insights, opines on the evolution of the global surface plasmon resonance market from 2014–2018, and presents demand projections for 2019–2029, on the basis of product type (imaging systems, sensor systems, and reagents), application (drug delivery, material science, and biosensors), and end user (academic and research institutes, food and beverage industry, biopharmaceutical companies, CROs, and others), across seven prominent regions.

Key players

  • GE Healthcare
  • AMETEK.Inc.
  • Horiba

Ask the Analyst @
https://www.futuremarketinsights.com/ask-question/rep-gb-962

Surface Plasmon Resonance Market By Category

By Product:

  • Imaging System
  • Sensor System
  • Reagents

By Application:

  • Drug Discovery
  • Material Science
  • Biosensors

By End User:

  • Academic & Research Institutes
  • Food & Beverage Industry
  • Biopharmaceutical Companies
  • CROs

About Future Market Insights (FMI) 

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact:

Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedInTwitterBlogs

Surgical Stapling Devices Market is anticipated to CAGR of 7.1% by 2031

According to a recent market study by Future Market Insights (FMI), the global market for surgical staplers was valued at US$ 2.8 billion in 2021 and is predicted to grow to US$ 6.2 billion by 2031.

The global demand for surgical stapling devices is propelling along with the world’s rising geriatric population. Lesser time consumed by surgical stapling devices for closing wounds, and the accuracy & precision of these devices is favouring their adoption for treating wounds of aged patients.

With deployment of advanced technologies, medical practitioners will keep adopting specialised devices that facilitate specific surgical operations in medical procedures. Rising number of invasive surgeries has necessitated the need for improved devices for wound management. And, surgical staples have effectively replaced sutures for closing wounds during such procedures.

Sample of Research Report @
https://www.futuremarketinsights.com/reports/sample/rep-gb-867

Future Market Insights recently published its report on the global market for surgical stapling devices, the highlights from which indicate that rising number of laparoscopic surgeries performed across the globe have triggered the use of surgical stapling devices.

In the report, titled “Surgical Stapling Devices Market: Global Industry Analysis and Opportunity Assessment, 2022-2031,” North America has been identified as the largest market for surgical stapling devices. By the end of forecast period, more than US$ 1,000 Mn revenues will be solely attributed by North America’s surgical stapling devices market.

Advanced healthcare infrastructure in Western Europe has facilitated the region’s surgical stapling devices market, which will register a value CAGR of 7.9% through 2031. Although, fastest consumption of surgical stapling devices will be witnessed in the Asia-Pacific excluding Japan (APEJ) region. The APEJ surgical stapling devices market is expected to soar at the highest CAGR of 8.6%.

Leading Manufacturers of Surgical Stapling Devices:

  • Medtronic plc
  • Grena Ltd.
  • Purple Surgical Holdings Limited
  • Dextera Surgical Inc.
  • Johnson & Johnson Services, Inc.
  • 3M Company
  • Meril Life Sciences Pvt. Ltd.

The report reveals that hospitals will remain the largest end-users of surgical stapling devices in the world – accounting for more than 60% of global revenues. Meanwhile, the demand for surgical stapling devices will also gain traction in ambulatory surgical centres.

Request Customization @
https://www.futuremarketinsights.com/customization-available/rep-gb-867

Key findings in the report indicate that powered surgical stapling devices worth US$ 1,182 Mn were sold globally in 2016, while the demand for manual surgical stapling products is anticipated to incur a downtrend in the years to come.

Throughout the forecast period, six out of ten surgical stapling devices sold in the world are likely to be disposable, while revenues from reusable surgical stapling products will be growing at a sluggish rate. Preference to curved surgical stapling is also on a rise, revenues from which are expected to soar impressively at 9% CAGR.

Dermatological surgeries will undoubtedly require greater number of surgical stapling devices. The report estimates that in 2016, nearly US$ 600 million revenues were amassed from the sales of surgical stapling devices in treatment of skin-related surgical wounds. The use of advanced surgical stapling devices is also expected to gain momentum for closing dissected or ruptured blood vessels during surgeries. Wounds situated in the patient’s digestive tract are also being treated by surgical stapling, and by the end of 2026, around US$ 665 million worth of devices will be consumed for such treatments.

Ask the Analyst @
https://www.futuremarketinsights.com/ask-question/rep-gb-867

We have segmented the global surgical stapling devices market into six sections. They are as follows:
By Region

  • North America
  • Latin America
  • Western Europe
  • Eastern Europe
  • APEJ
  • Japan
  • MEA

By End User

  • Hospitals
  • Ambulatory Surgical Centres
  • Others

By Stapling Type

  • Straight
  • Curved
  • Circular

By Usage Type

  • Disposable Surgical Stapling Devices
  • Reusable Surgical Stapling Devices

By Indication

  • Skin
  • Digestive Tract
  • Blood Vessels
  • Hernia
  • Lungs
  • Others

By Product

  • Powered Surgical Stapling Devices
  • Manual Surgical Stapling Devices

About Future Market Insights (FMI) 

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact:

Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedInTwitterBlogs